Macrogenics Stock Today
| MGNX Stock | USD 1.83 0.04 2.23% |
PerformanceSoft
| Odds Of DistressStrong
|
MacroGenics is trading at 1.83 as of the 10th of January 2026; that is 2.23 percent increase since the beginning of the trading day. The stock's open price was 1.79. MacroGenics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 12th of October 2025 and ending today, the 10th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of October 2013 | Category Healthcare | Classification Health Care |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 63.26 M outstanding shares of which 3.85 M shares are now shorted by private and institutional investors with about 2.89 trading days to cover. More on MacroGenics
Moving against MacroGenics Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
MacroGenics Stock Highlights
| CEO President | Scott MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMacroGenics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MacroGenics' financial leverage. It provides some insight into what part of MacroGenics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MacroGenics (MGNX) is traded on NASDAQ Exchange in USA and employs 341 people. MacroGenics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 115.76 M. MacroGenics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.26 M outstanding shares of which 3.85 M shares are now shorted by private and institutional investors with about 2.89 trading days to cover.
MacroGenics currently holds about 133.74 M in cash with (68.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check MacroGenics Probability Of Bankruptcy
Ownership AllocationMacroGenics maintains a total of 63.26 Million outstanding shares. Over half of MacroGenics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MacroGenics Ownership Details
MacroGenics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2025-06-30 | 698.3 K | |
| Geode Capital Management, Llc | 2025-06-30 | 683.5 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 682.3 K | |
| Dimensional Fund Advisors, Inc. | 2025-06-30 | 508.8 K | |
| Jpmorgan Chase & Co | 2025-06-30 | 460.1 K | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 446.2 K | |
| Macquarie Group Ltd | 2025-06-30 | 420 K | |
| Two Sigma Investments Llc | 2025-06-30 | 407.3 K | |
| Marshall Wace Asset Management Ltd | 2025-06-30 | 405.9 K | |
| Bellevue Group Ag | 2025-06-30 | 9.9 M | |
| Armistice Capital, Llc | 2025-06-30 | 6 M |
MacroGenics Historical Income Statement
MacroGenics Stock Against Markets
MacroGenics Corporate Management
| Eric Risser | Sr. VP of Bus. Devel. and Portfolio Management | Profile | |
| Beth Smith | Controller VP | Profile | |
| Steve Harig | Senior Resources | Profile | |
| Christopher MD | VP Communications | Profile | |
| Harish Krishnaswamy | Senior Planning | Profile | |
| Ezio MD | Senior Officer | Profile |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.